The global market for Molecular Residual Disease Detection was valued at US$ 6164 million in the year 2024 and is projected to reach a revised size of US$ 16770 million by 2031, growing at a CAGR of 15.6% during the forecast period.
Molecular residual lesions often refer to minimal residual lesions, which refer to a small number of cancer cells that remain in the body after cancer treatment (cancer cells that do not respond to treatment or are drug-resistant).
North American market for Molecular Residual Disease Detection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Molecular Residual Disease Detection is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Molecular Residual Disease Detection in Prognosis is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Molecular Residual Disease Detection include Adaptive, Guardant Health, Invitae, Cergentis B.V, LexentBio, Natera, BGI, Zhiben Medical, Burning Rock Medicine, Huidu Medical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Molecular Residual Disease Detection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Residual Disease Detection.
The Molecular Residual Disease Detection market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Molecular Residual Disease Detection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Molecular Residual Disease Detection companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Adaptive
Guardant Health
Invitae
Cergentis B.V
LexentBio
Natera
BGI
Zhiben Medical
Burning Rock Medicine
Huidu Medical
Zhenhe Technology
ExactSciences
Segment by Type
Tumor-informed Assays
Tumor-agnostic Assays
Segment by Application
Prognosis
Adjuvant Treatment Decision-Making
Surveillance for Postoperative Recurrence
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Molecular Residual Disease Detection company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Residual Disease Detection Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Tumor-informed Assays
1.2.3 Tumor-agnostic Assays
1.3 Market by Application
1.3.1 Global Molecular Residual Disease Detection Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Prognosis
1.3.3 Adjuvant Treatment Decision-Making
1.3.4 Surveillance for Postoperative Recurrence
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Molecular Residual Disease Detection Market Perspective (2020-2031)
2.2 Global Molecular Residual Disease Detection Growth Trends by Region
2.2.1 Global Molecular Residual Disease Detection Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Molecular Residual Disease Detection Historic Market Size by Region (2020-2025)
2.2.3 Molecular Residual Disease Detection Forecasted Market Size by Region (2026-2031)
2.3 Molecular Residual Disease Detection Market Dynamics
2.3.1 Molecular Residual Disease Detection Industry Trends
2.3.2 Molecular Residual Disease Detection Market Drivers
2.3.3 Molecular Residual Disease Detection Market Challenges
2.3.4 Molecular Residual Disease Detection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Residual Disease Detection Players by Revenue
3.1.1 Global Top Molecular Residual Disease Detection Players by Revenue (2020-2025)
3.1.2 Global Molecular Residual Disease Detection Revenue Market Share by Players (2020-2025)
3.2 Global Molecular Residual Disease Detection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Molecular Residual Disease Detection Revenue
3.4 Global Molecular Residual Disease Detection Market Concentration Ratio
3.4.1 Global Molecular Residual Disease Detection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Residual Disease Detection Revenue in 2024
3.5 Global Key Players of Molecular Residual Disease Detection Head office and Area Served
3.6 Global Key Players of Molecular Residual Disease Detection, Product and Application
3.7 Global Key Players of Molecular Residual Disease Detection, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Residual Disease Detection Breakdown Data by Type
4.1 Global Molecular Residual Disease Detection Historic Market Size by Type (2020-2025)
4.2 Global Molecular Residual Disease Detection Forecasted Market Size by Type (2026-2031)
5 Molecular Residual Disease Detection Breakdown Data by Application
5.1 Global Molecular Residual Disease Detection Historic Market Size by Application (2020-2025)
5.2 Global Molecular Residual Disease Detection Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Molecular Residual Disease Detection Market Size (2020-2031)
6.2 North America Molecular Residual Disease Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Molecular Residual Disease Detection Market Size by Country (2020-2025)
6.4 North America Molecular Residual Disease Detection Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Molecular Residual Disease Detection Market Size (2020-2031)
7.2 Europe Molecular Residual Disease Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Molecular Residual Disease Detection Market Size by Country (2020-2025)
7.4 Europe Molecular Residual Disease Detection Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Residual Disease Detection Market Size (2020-2031)
8.2 Asia-Pacific Molecular Residual Disease Detection Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Molecular Residual Disease Detection Market Size by Region (2020-2025)
8.4 Asia-Pacific Molecular Residual Disease Detection Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Molecular Residual Disease Detection Market Size (2020-2031)
9.2 Latin America Molecular Residual Disease Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Molecular Residual Disease Detection Market Size by Country (2020-2025)
9.4 Latin America Molecular Residual Disease Detection Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Residual Disease Detection Market Size (2020-2031)
10.2 Middle East & Africa Molecular Residual Disease Detection Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Molecular Residual Disease Detection Market Size by Country (2020-2025)
10.4 Middle East & Africa Molecular Residual Disease Detection Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Adaptive
11.1.1 Adaptive Company Details
11.1.2 Adaptive Business Overview
11.1.3 Adaptive Molecular Residual Disease Detection Introduction
11.1.4 Adaptive Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.1.5 Adaptive Recent Development
11.2 Guardant Health
11.2.1 Guardant Health Company Details
11.2.2 Guardant Health Business Overview
11.2.3 Guardant Health Molecular Residual Disease Detection Introduction
11.2.4 Guardant Health Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.2.5 Guardant Health Recent Development
11.3 Invitae
11.3.1 Invitae Company Details
11.3.2 Invitae Business Overview
11.3.3 Invitae Molecular Residual Disease Detection Introduction
11.3.4 Invitae Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.3.5 Invitae Recent Development
11.4 Cergentis B.V
11.4.1 Cergentis B.V Company Details
11.4.2 Cergentis B.V Business Overview
11.4.3 Cergentis B.V Molecular Residual Disease Detection Introduction
11.4.4 Cergentis B.V Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.4.5 Cergentis B.V Recent Development
11.5 LexentBio
11.5.1 LexentBio Company Details
11.5.2 LexentBio Business Overview
11.5.3 LexentBio Molecular Residual Disease Detection Introduction
11.5.4 LexentBio Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.5.5 LexentBio Recent Development
11.6 Natera
11.6.1 Natera Company Details
11.6.2 Natera Business Overview
11.6.3 Natera Molecular Residual Disease Detection Introduction
11.6.4 Natera Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.6.5 Natera Recent Development
11.7 BGI
11.7.1 BGI Company Details
11.7.2 BGI Business Overview
11.7.3 BGI Molecular Residual Disease Detection Introduction
11.7.4 BGI Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.7.5 BGI Recent Development
11.8 Zhiben Medical
11.8.1 Zhiben Medical Company Details
11.8.2 Zhiben Medical Business Overview
11.8.3 Zhiben Medical Molecular Residual Disease Detection Introduction
11.8.4 Zhiben Medical Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.8.5 Zhiben Medical Recent Development
11.9 Burning Rock Medicine
11.9.1 Burning Rock Medicine Company Details
11.9.2 Burning Rock Medicine Business Overview
11.9.3 Burning Rock Medicine Molecular Residual Disease Detection Introduction
11.9.4 Burning Rock Medicine Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.9.5 Burning Rock Medicine Recent Development
11.10 Huidu Medical
11.10.1 Huidu Medical Company Details
11.10.2 Huidu Medical Business Overview
11.10.3 Huidu Medical Molecular Residual Disease Detection Introduction
11.10.4 Huidu Medical Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.10.5 Huidu Medical Recent Development
11.11 Zhenhe Technology
11.11.1 Zhenhe Technology Company Details
11.11.2 Zhenhe Technology Business Overview
11.11.3 Zhenhe Technology Molecular Residual Disease Detection Introduction
11.11.4 Zhenhe Technology Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.11.5 Zhenhe Technology Recent Development
11.12 ExactSciences
11.12.1 ExactSciences Company Details
11.12.2 ExactSciences Business Overview
11.12.3 ExactSciences Molecular Residual Disease Detection Introduction
11.12.4 ExactSciences Revenue in Molecular Residual Disease Detection Business (2020-2025)
11.12.5 ExactSciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Adaptive
Guardant Health
Invitae
Cergentis B.V
LexentBio
Natera
BGI
Zhiben Medical
Burning Rock Medicine
Huidu Medical
Zhenhe Technology
ExactSciences
听
听
*If Applicable.
